After Ranbaxy was acquired by Daichii Sankyo last year than this year again at perhaps same time another Japanese company Hisamitsu Pharmaceutical bought Miami-based Noven Pharmaceutical for $430 million. Hisamitsu Pharmaceutical is interested in expanding in the U.S., Hisamitsu agreed to pay $16.50 a share, a 38 percent premium on the company's 50-day close. Hisamitsu plans to make the company with specialization in hormone therapies to be a wholly-owned subsidiary of the Japanese firm, Today’s headline is that one more Japanese firm and Nycomed are in the early second round of an auction for all of Solvay's pharmaceuticals business.....this time we have Japanese in race with US and UK based companies in global M&A.
Thursday, July 16, 2009
Japanese pharma on M&A move ............................
After Ranbaxy was acquired by Daichii Sankyo last year than this year again at perhaps same time another Japanese company Hisamitsu Pharmaceutical bought Miami-based Noven Pharmaceutical for $430 million. Hisamitsu Pharmaceutical is interested in expanding in the U.S., Hisamitsu agreed to pay $16.50 a share, a 38 percent premium on the company's 50-day close. Hisamitsu plans to make the company with specialization in hormone therapies to be a wholly-owned subsidiary of the Japanese firm, Today’s headline is that one more Japanese firm and Nycomed are in the early second round of an auction for all of Solvay's pharmaceuticals business.....this time we have Japanese in race with US and UK based companies in global M&A.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment